Rigel Reports Second Quarter 2026 Financial Results
Rigel reported Q2 2026 total revenue of $78.7 million, driven by a 14% year-over-year increase in net product sales to $67.0 million, and achieved net income of $17.3 million. Management raised full-year 2026 revenue guidance to $285 million to $295 million, citing strong commercial performance and increased collaboration revenue expectations. The company expanded its portfolio by in-licensing VEPPANU from Arvinas and Pfizer for a $70 million upfront payment, with U.S.
Key figures
- Eps
- 0.88
- Revenue
- $78.7 million
- Guidance
- 2026 total revenues of approximately $285 to $295 million, raised from $275 to $290 million
- Net income
- $17.3 million
- Cash position
- $95.3 million
- Net product sales
- $67.0 million
- Product sales yoy
- 14%
- Collaboration revenue
- $11.7 million
- Upfront payment veppanu
- $70.0 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.